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Abstract 
Background: Atrial natriuretic peptide increases lipolysis in human 
adipocytes by binding to natriuretic peptide receptor-A (NPRA). The aim of 
the current study was to examine the associations of NPRA mRNA of 
subcutaneous adipose tissue with fat mass, fat-free mass, body mass index 
(BMI) and arterial blood pressure in medication-free healthy men. 
Method: Thirty-two volunteers [age (years): 36.06±7.36, BMI: 27.60±4.63 
(kg/m 2)] underwent assessments of body height/weight, % fat mass, fat-free 
mass (kg), blood pressure, and a subcutaneous adipose tissue biopsy via a 
surgical technique. 
Results: We found that NPRA mRNA was negatively associated with % fat 
mass (r=-0.40, R 2=0.16, p=0.03) and BMI (r=-0.45, R 2=0.20, p=0.01). 
Cohen’s f 2 effect size analyses showed a small effect size between NPRA 
mRNA and BMI ( f 2 =0.25). One-way analysis of variance with Bonferroni 
post-hoc tests showed a tendency for mean differences of NPRA mRNA 
across BMI categories (p=0.06). This was confirmed by Cohen’s d effect size 
analyses revealing a large effect size of NPRA mRNA between obese 
individuals (BMI≥30 kg/m 2) and either normal weight (BMI=19-25 kg/m 2; 
d=0.94) or overweight (BMI=25-30 kg/m 2; d=1.12) individuals. 
Conclusions: NPRA mRNA is negatively associated with % fat mass and 
BMI in medication-free healthy men, suggesting a possible role of NPRA in 
the control of fat mass accumulation. 
 
Introduction 
Atrial natriuretic peptide (ANP) lowers arterial pressure to maintain fluid volume 
homeostasis, thus protecting against renal and cardiac pathogenesis 1 . ANP also increases 
lipolysis in human adipocytes 2 by binding to natriuretic peptide receptor-A (NPRA) 3 . 
NPRA is less expressed in subcutaneous adipose tissue (SAT) in obese individuals and type 2 
diabetes patients than in normal glucose tolerant individuals 4 . Also, NPRA signalling in 
skeletal muscle may enhance long-term insulin sensitivity 5 . Collectively, NPRA may 
potentially treat obesity-related disorders while ANP may play a role in the therapeutic 
mechanisms of beta-adrenoceptor antagonists in the mitigation of heart dysfunction and 
utilization of lipid mobilization 6 . However, the role of ANP in lipolysis has been primarily 
investigated mainly in vitro models 7– 9 , in human blood cells from individuals under 
medication treatment 10 , and in animal models 9 . To our knowledge, no such information is 
currently available in relation to the role of its receptor (NPRA) on the adipocytes of healthy 
individuals. Therefore, the aim of the current study was to examine the associations of NPRA 
mRNA of SAT with fat mass, fat-free mass (FFM), body mass index (BMI) and arterial 
blood pressure (BP) in medication-free healthy men. 
Methods 
The study was approved by the Ethics Committee of the University of Thessaly (protocol no. 
698/2013). The inclusion criteria were: healthy adult men, non-smokers, no chronic disease 
and/or being under medication treatment. The participants were recruited by advertisements 
in a local newspaper in Trikala, Thessaly, Greece and the data collection started in July 2013 
and ended in June 2014. Written consent was obtained from the 32 healthy men recruited 
[age (years): 36.06±7.36, BMI: 27.60±4.63 (kg/m 2)]. 
To avoid misleading results, the participants refrained from exercise, alcohol, and passive 
smoking 72h prior the measurements, while they followed an overnight fast before they visit 
the physiology laboratory in the School of Exercise Science between 07:00–09:00 am. PCD 
and DP performed the following measurements: body height using a Seca 220 (Hamburg, 
Germany) stadiometer, body weight using a precision scale (KERN & Sohn GmbH, Version 
5.3, Germany) and blood pressure (BP) using a Standard Aneroid sphygmomanometer 
(Medisave, UK) according to standard guidelines24. Briefly, participants were instructed to 
empty their bladders and seat for five minutes in a relaxed back rest position without 
speaking. BP readings were taken twice, each two minutes apart, while the mean of the two 
BP readings was considered as the final BP values. Fat mass percentage (%FM) and FFM 
were measured via bioelectrical impedance using a body composition monitor (Fresenius 
Medical Care AG & Co. KGaA D-61346 Bad Hamburg, Germany). 
Following the aforementioned measurements, the participants underwent a SAT biopsy in the 
physiology laboratory by a trained physician, as previously described 11 . Briefly, the site of 
the incision was disinfected and a 10 ml of 2% xylocaine (no adrenaline) was injected for 
local anaesthesia. An incision of 2–2.5 cm was made 3–5 cm to the left of the navel. Nearly 
500 mg of subcutaneous adipose tissue was captured and removed. The NPRA mRNA 
analysis of SAT samples is described elsewhere 12 . Briefly, total RNA was extracted using 
RNeasy Lipid Tissue mini kit (QIAGEN). First-strand cDNAs were synthesized from equal 
amounts of total RNA using random primers and M-MLV reverse transcriptase (Promega). 
Quantitative real-time polymerase chain reaction was performed using Sybr Green 
fluorophore. 18S rRNA gene was used as a reference for normalization. 
Following previous methodology, we removed two mean values (i.e. outliers) of NPRA 
mRNA that were at a distance of more than two standard deviations from the mean of the 
distribution 13, 14 . Also, there were three missing values in the NPRA mRNA analysis of SAT 
samples due to failure to extract RNA from adipose tissue. Eventually, 27 NPRA mRNA 
values were included in the statistical analysis using SPSS (version 24; SPSS Inc., Chicago, 
IL, USA). Normal distribution was determined using Shapiro-Wilk test, whereas Pearson’s 
correlation coefficient, linear regression, and Cohen’s f 2 effect size (R 2/1-R 2) 15 were used 
to detect associations between NPRA mRNA, %FM, FFM (kg), BMI, and BP. We also used 
one-way analysis of variance (ANOVA) with Bonferroni post-hoc tests, and Cohen’s d effect 
size analyses to explore the mean differences of NPRA mRNA across different BMI 
categories [normal weight <25 kg/m 2 (n=9); overweight 25–30 kg/m 2 (n=9); obese >30 
kg/m 2 (n=9)]. The level of significance was set at p≤0.05. 
Results 
The participants’ characteristics are provided in Table 1. The NPRA mRNA was negatively 
correlated with %FM (r=-0.40, p=0.03) ( Figure 1) and BMI (r=-0.45, p=0.01) ( Figure 2). 
No associations were found between NPRA mRNA and FFM, systolic or diastolic BP 
(p>0.05). 
Linear regression analyses confirmed the associations between NPRA mRNA and %FM (R 
2=0.16, p=0.03) as well as BMI (R 2=0.20, p=0.01). Cohen’s f 2 effect size analyses showed a 
small effect size between NPRA mRNA and BMI ( f 2 =0.25), however, no effect size was 
detected between NPRA mRNA and %FM ( f 2 <0.20). ANOVA demonstrated a strong 
tendency for mean differences in NPRA mRNA across BMI categories (p=0.06). This was 
confirmed by Cohen’s d effect size analyses in NPRA mRNA, revealing large effect sizes 
between obese individuals (BMI≥30 kg/m 2) and either normal weight (BMI <25 kg/m 2; 
d=0.94) or overweight (BMI=25–30 kg/m 2; d=1.12) individuals. 
Table 1. Characteristics of the participants. 
Age (years) (n=32) 36.06±7.36 
BMI (kg/m 2) (n=32) 27.60±4.62 
Fat mass (%) (n=32) 28.32±8.87 
Fat free mass (kg) (n=32) 52.90±5.02 
Systolic blood pressure (mmHg) (n=32) 124.28±10.09 
Diastolic blood pressure (mmHg) (n=32) 84.28±6.91 
[i] BMI: Body mass index 
 
Figure 1. Association of NPRA mRNA with fat mass %. 
 
Figure 2. Association of NPRA mRNA with body mass index. 
Dataset 1.Subcutaneous adipose tissue NPRA mRNA of medication-free healthy men.  
BMI=Body mass index; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; FFM=Fat-free 
mass; NPRA= Natriuretic peptide receptor-A. BMI categories= 1. <25 kg/m 2, 2. 25–30 kg/m 2, 3. >30 
kg/m 2. 
Click here to access the data. 
10.5256/f1000research.14198.d197694 
Discussion and conclusions 
We have shown that the NPRA mRNA is negatively associated with %FM and BMI in 
medication-free healthy men and that it is expressed less in obese compared to lean 
individuals. Previous evidence showed that NPRA mRNA is expressed less in normal 
glucose tolerant individuals than in type 2 diabetes patients 4 , while it is positively associated 
with insulin sensitivity 4 . Given that insulin sensitivity is negatively associated with 
excessive FM in humans 16, 17 the inverse association of NPRA mRNA with %FM and BMI 
observed in the current study suggests a possible role of NPRA in lowering FM in humans. 
Indeed, it has been established that natriuretic peptides by binding to NPRA, increase cyclic 
guanosine monophosphate – a well-known intracellular second messenger – which 
phosphorylates protein kinase G leading to activation of hormone sensitive lipase 18, 19 . This 
process mediates triglyceride degradation (i.e. lipolysis), which subsequently increases fatty 
acid availability 18 . Furthermore, findings in mice showed that the lack of NPRA gene may 
increase FM 9 . Also, NPRA signalling as part of ANP/NPRA axis may induce a browning of 
white adipocytes, indicates increased energy expenditure and thus, a potential to lessen 
obesity30.    
 
The current study may be affected by methodological limitations such as the lack of insulin 
sensitivity measurements and a priori power calculation to determine the sample size. 
However, a post-measurements power calculation was conducted using an online software 
(DSS Research) to test statistical power. This revealed 89% of statistical power for the 27 
available samples, based on the NPRA mRNA value (1.02±0.38) we detected in our study 
and expected NPRA mRNA value (0.81±0.08) from a previous similar study that examined 
NPRA in SAT in humans 4 . Another limitation was the lack of triglyceride, cholesterol and 
ANP plasma levels, to determine whether there is an association with NPRA mRNA, given 
the association of the aforementioned factors with lipolysis 2, 18. Previous evidence also 
suggests that, large adipocytes express higher NPRA mRNA than small adipocytes, indicates 
enhanced ANP-stimulated lipolysis in large adipocytes25. However, we include no analysis to 
determine the size of the examined adipocytes and its possible association with NPRA 
mRNA. Furthermore, brain natriuretic peptide (BNP) may alter expression of NPRA to 
release free fatty acids from adipose tissue, while obesity is inversely associated with 
circulating BNP, a situation known as “natriuretic handicap” 26, 27. Nevertheless, circulating 
BNP was not measured in our study to examine whether there is an association with NPRA 
mRNA. Also, ANP may inhibit the secretion of adipokines and cytokines from adipose 
tissue, thus may decrease chronic inflammation and insulin resistance28,29, however, ANP 
levels were not determined in our study. It would also be helpful to determine hormone 
sensitive lipase in the current study, given the action of ANP/BNP on lipolytic hormones2,6. 
Finally, the current results are limited to the Greek population and male participants, 
therefore, they should be treated with caution when apply to other ethnicities and females.    
 
 
In conclusion, NPRA mRNA is negatively associated with %FM and BMI in medication-free 
healthy men, suggesting a possible role of ANP/NPRA axis in the control of FM 
accumulation. To date, the investigation of NPRA has mainly focused either on circulating 
and muscle NPRA 20– 22 or on medication-dependent NPRA measurements 4, 10 . Our study 
indicates that NPRA may also play role in FM profile of healthy individuals, which should be 
further explored in a cause-and-effect research setting. 
Data availability 
Dataset 1: Subcutaneous adipose tissue NPRA mRNA of medication-free healthy men 
10.5256/f1000research.14198.d197694 23  
BMI=Body mass index; SBP=Systolic blood pressure; DBP=Diastolic blood pressure; 
FFM=Fat-free mass; NPRA= Natriuretic peptide receptor-A. 
BMI categories= 1. <25 kg/m 2, 2. 25–30 kg/m 2, 3. >30 kg/m 2. 
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